Chimeron Bio & George Mason NCBID partner on COVID-19 vaccine using ChaESARTM technology
(George Mason University) RNA therapeutics company, Chimeron Bio and George Mason University's National Center for Biodefense and Infectious Diseases (NCBID) announced their partnership to develop a Coronavirus (COVID-19) vaccine based on Chimeron Bio's ChaESARTM self-amplifying RNA technology and will integrate Mason's complimenting expertise and Biomedical Research Laboratory (BRL), a National Institute of Allergy and Infectious Diseases/National Institutes of Health (NIAID/NIH) supported, state-of-the-art Regional Biocontainment Laboratory for the rapid screening of the company's vaccine pipeline.
Source: EurekAlert! - Infectious and Emerging Diseases - Category: Infectious Diseases Source Type: news
More News: Allergy | Allergy & Immunology | Coronavirus | COVID-19 | Infectious Diseases | Laboratory Medicine | National Institutes of Health (NIH) | Partnerships | Vaccines